New drug combo before surgery for HR+, HER2+ breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new drug called SHR-A1811 combined with pertuzumab given before surgery to shrink tumors in people with early or locally advanced, hormone receptor-positive and HER2-positive breast cancer. It is designed to see if this combination can help reduce tumor size better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 70 years old.
- You have been diagnosed with invasive breast cancer that is both hormone receptor-positive and HER2-positive.
- You have not had any previous treatment for your breast cancer (like chemotherapy, radiation, or hormone therapy).
- Your cancer is stage II or III, meaning it is large or has spread to lymph nodes but not to distant organs.
- You must be in generally good health (able to do daily activities) and your heart, blood, and kidney function must be within certain limits on blood tests.
- If you can get pregnant, you need a negative pregnancy test before starting and must use reliable birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called SHR-A1811 for women with HER2-positive breast cancer that did not shrink enough after 4 cycles of standard pre-surgery treatment. The goal is to see if this drug can help improve outcomes before surgery.
This trial tests a combination of two targeted drugs (SHR-A1811 and pertuzumab) given before surgery to shrink HER2-positive breast cancer. It aims to see if this approach improves outcomes for patients with early-stage but high-risk disease.
This trial tests a new drug (SHR-A1811) alone or with another drug (adebrelimab) before surgery for women with a specific type of early-stage breast cancer called HR+, HER2-low. The goal is to see if this combination can shrink the tumor before surgery, possibly leading to better outcomes.
This study tests a new drug called SHR-A1811 combined with pertuzumab (Perjeta) before surgery for patients with HER2-positive breast cancer that has not spread beyond the breast and nearby lymph nodes. The goal is to shrink the cancer before surgery and improve outcomes.
This trial tests a new drug called SHR-A1811, given either alone or with the hormone therapy letrozole, before surgery for women with early-stage breast cancer that is hormone receptor positive and HER2-low. The goal is to see if this treatment can shrink the tumor before surgery.
This trial tests SHR-A1811 given before surgery (neoadjuvant treatment) for breast cancer that is hormone-receptor positive (HR-positive) and HER2-low. It aims to shrink or control the cancer early and see how well this approach works compared with standard care.
Hear when a new HR+ Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.